• Return to Headlines

Shares of Epizyme Inc Rank the Lowest in Terms of Debt-to-Capital Ratio in the Biotechnology Industry (EPZM, ACHN, MGNX, ENTA, NLNK)

By James Quinn

Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Epizyme Inc ranks lowest with a a Debt-to-Capital ratio of 4.7%. Achillion Pharma is next with a a Debt-to-Capital ratio of 9.3%. Macrogenics Inc ranks third lowest with a a Debt-to-Capital ratio of 9.9%.

Enanta Pharmaceu follows with a a Debt-to-Capital ratio of 15.2%, and Newlink Genetics rounds out the bottom five with a a Debt-to-Capital ratio of 17.8%.

SmarTrend recommended that its subscribers protect gains by selling shares of Newlink Genetics on April 18th, 2019 by issuing a Downtrend alert when the shares were trading at $1.59. Since that call, shares of Newlink Genetics have fallen 4.7%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest debt-to-capital ratio epizyme inc achillion pharma macrogenics inc enanta pharmaceu newlink genetics

Ticker(s): EPZM ACHN MGNX ENTA NLNK